Based on genetic alterations such as mutations in V-Ki-ras2 Kirsten Rat Sarcoma viral oncogene homolog (KRAS) and proto-oncogene B-Raf (BRAF), and mutations or methylation of Mismatch Repair (MMR) genes, several specific treatments of molecular CRC subgroups have emerged over recent years [5]. The gene discussed is KRAS; the disease is colorectal carcinoma.